Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Nanomedicine ; 12(1): 201-11, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26515754

ABSTRACT

Fumagillin, an unstable anti-angiogenesis mycotoxin, was synthesized into a stable lipase-labile prodrug and incorporated into integrin-targeted lipid-encapsulated nanoparticles (αvß3-Fum-PD NP). Dual anti-angiogenic therapy combining αvß3-Fum-PD NP with zoledronic acid (ZA), a long-acting osteoclast inhibitor with proposed anti-angiogenic effects, was evaluated. In vitro, αvß3-Fum-PD NP reduced (P<0.05) endothelial cell viability without impacting macrophage viability. ZA suppressed (P<0.05) macrophage viability at high dosages but not endothelial cell proliferation. 3D MR neovascular imaging of rabbit Vx2 tumors showed no effect with ZA, whereas αvß3-Fum-PD NP alone and with ZA decreased angiogenesis (P<0.05). Immunohistochemistry revealed decreased (P<0.05) microvascularity with αvß3-Fum-PD NP and ZA and further microvascular reduction (P<0.05) with dual-therapy. In vivo, ZA did not decrease tumor macrophage numbers nor cancer cell proliferation, whereas αvß3-Fum-PD-NPs reduced both measures. Dual-therapy with ZA and αvß3-Fum-PD-NP may provide enhanced neo-adjuvant utility if macrophage ZA uptake is increased. From the Clinical Editor: Although anti-angiogenesis is one of the treatment modalities in the fight against cancer, many cancers become resistant to VEGF pathway inhibitors. In this article, the authors investigated the use of dual therapy using fumagillin, integrin-targeted lipid-encapsulated nanoparticles (αvß3- Fum-PD NP) and zoledronic acid (ZA), in both in-vitro and in-vivo experiments. This combination approach may provide an insight to the design of future drugs against cancers.


Subject(s)
Amino Acid Transport Systems, Neutral/pharmacokinetics , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Diphosphonates/administration & dosage , Imidazoles/administration & dosage , Integrin alphaVbeta3/metabolism , Neoplasms, Experimental/drug therapy , Prodrugs/administration & dosage , Angiogenesis Inhibitors/administration & dosage , Angiogenesis Inhibitors/chemistry , Animals , Antineoplastic Combined Chemotherapy Protocols/chemistry , Cell Line, Tumor , Diffusion , Diphosphonates/chemistry , Imidazoles/chemistry , Male , Molecular Targeted Therapy/methods , Nanocapsules/administration & dosage , Nanocapsules/chemistry , Neoplasms, Experimental/metabolism , Neoplasms, Experimental/pathology , Prodrugs/chemistry , Rabbits , Treatment Outcome , Zoledronic Acid
2.
Biomater Sci ; 3(7): 1105-13, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26221944

ABSTRACT

Polymeric nanoparticles have been widely used as nano-drug delivery systems in preclinical and clinical trials for cancer therapy, and these systems usually need to be sterically stabilized by poly(ethylene glycol) (PEG) to maintain stability and avoid rapid clearance by the immune system. Recently, zwitterionic materials have been demonstrated to be potential alternatives to the classic PEG. Herein, we developed two drug delivery systems stabilized by zwitterionic polyphosphoesters. These nanoparticles showed favourable stability and anti-protein absorption ability in vitro. Meanwhile, as drug carriers, these zwitterionic polyphosphoester-stabilized nanoparticles significantly prolonged drug circulation half-lives and increased drug accumulation in tumors, which was comparable to PEG-stabilized nanoparticles. Systemic delivery of doxorubicin (DOX) by zwitterionic polyphosphoester-stabilized nanoparticles significantly inhibited tumor growth in a MDA-MB-231 tumor model, suggesting the potential of zwitterionic polyphosphoester-based nanoparticles in anticancer drug delivery.


Subject(s)
Amino Acid Transport Systems, Neutral/chemistry , Doxorubicin/therapeutic use , Drug Delivery Systems/methods , Nanoparticles/chemistry , Polyethylene Glycols/chemistry , Polymers/chemistry , Amino Acid Transport Systems, Neutral/pharmacokinetics , Cell Line, Tumor , Doxorubicin/chemistry , Drug Carriers , Humans , Hydrogen-Ion Concentration
SELECTION OF CITATIONS
SEARCH DETAIL
...